Safety, efficacy and immunogenicity of concomitant interferon alpha and autologous tumor lysate-pulsed dendritic cell therapy in patients with advanced renal cell carcinoma
Not Applicable
- Conditions
- Renal cell carcinoma
- Registration Number
- JPRN-UMIN000006646
- Lead Sponsor
- The University of Tokyo Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who have: -Pulmonary fibrosis or interstitial pneumonia, or history or predisposition of them; -Serious drug allergy; -Active infections; -Serious cardiac disease; -Active autoimmune diseases; -Continuous systemic administration of steroids within 4 weeks; -Other cancers.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety
- Secondary Outcome Measures
Name Time Method Immunological responses Antitumor effect Overall survival Progression-free survival